Panel Discussion: Discussing the Latest on the Need for Lymphodepletion in Cell Therapies to Improve Patient Access & Limit Therapeutic Side Effects

Time: 9:00 am
day: Conference Day Two P1

Details:

• Identify why lymphodepletion has been used in autoimmune cell therapies
• Examine the impact of lymphodepletion on patient recruitment and accessibility
• Consider the advantages and opportunities to remove preconditioning from therapies

Speakers:

Jim Sesic Jim Sesic, is a seasoned regulatory executive with over 20 years of experience across the pharmaceutical, biotech, and cell and gene therapy sectors. As Head Read more

Fred Aslan Fred Aslan, M.D. brings two decades of leadership in the life sciences industry as an executive, investor, and entrepreneur. Most recently, he served as President Read more

Milos Miljkovic